January 30, 2014 / 6:46 AM / 4 years ago

Novo Nordisk edges 2014 guidance up after weak Q4

COPENHAGEN, Jan 30 (Reuters) - Denmark's Novo Nordisk edged its financial guidance for 2014 higher, saying it now expects sales to grow by 8-11 percent and operating profit to grow by around 10 percent in local currencies.

In October the insulin producer said it expected high single-digit growth in sales and operating profit in 2014 in local currencies.

Operating profit fell to 7.35 billion Danish crowns ($1.34 billion) in the fourth quarter, missing forecasts in a Reuters poll.

Novo's board proposed a dividend of 4.5 crowns per share and a 12-month share buyback programme of up to 15 billion crowns.

$1 = 5.4691 Danish crowns Reporting by Teis Jensen and Shida Chayesteh; Editing by John Stonestreet

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below